Rusul Al-Marayaty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rusul Al-Marayaty has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Seth M. Pollack
Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
17 shared publications - Ali Zhang
Northwestern University 2 , Feinberg School of Medicine, Chicago, Illinois
16 shared publications - Alonso Villasmil Ocando
Obsidian Therapeutics, Cambridge, Massachusetts
16 shared publications - Andres Alvarado
Obsidian Therapeutics, Cambridge, Massachusetts
16 shared publications - Bulent Arman Aksoy
Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina
16 shared publications - Dexue Sun
Obsidian Therapeutics, Cambridge, Massachusetts
16 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S7 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Supplementary Table 1 Baseline Patient Characteristics Supplementary Table 2 Treatment-Related Adverse Events. Supplementary Table 3 Summary Statistics for PFS, OS, and ORR Across Treatment Arms A, B, and C Supplementary Table 4 Peripheral Immune Cell Phenotypes. Supplementary Table 5 Best Overall Response and Confidence Intervals in the Evaluable Cohort Supplementary Table 6 Clinical Predictors of Hyperprogresson Supplementary Table 7 Univariate and Multivariate Associations With Overall Survival in SCLC in IMpower133
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S7 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Supplementary Table 1 Baseline Patient Characteristics Supplementary Table 2 Treatment-Related Adverse Events. Supplementary Table 3 Summary Statistics for PFS, OS, and ORR Across Treatment Arms A, B, and C Supplementary Table 4 Peripheral Immune Cell Phenotypes. Supplementary Table 5 Best Overall Response and Confidence Intervals in the Evaluable Cohort Supplementary Table 6 Clinical Predictors of Hyperprogresson Supplementary Table 7 Univariate and Multivariate Associations With Overall Survival in SCLC in IMpower133
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S9 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Figure S1. Adverse Events Following Treatment with Bintrafusp alfa Figure S2. Progression-free Survival and Overall Survival for All Arms Figure S3. Transcriptional Differences Underlying Clinical Benefit Figure S4. Comparison of HPD rates and survival between bintrafusp alfa and historical topotecan-based controls in relapsed SCLC Figure S5. Comparison of hyperprogressive disease with dual TGF-β/PD-L1 blockade (bintrafusp alfa) across tumor types. Figure S6. Distribution of SCLC Molecular Subtypes and Associated Gene Expression Differences n HPD and non-HPD Patients Figure S7. Functional Effects of TGF-β Signaling and Bintrafusp alfa in SCLC Cell Lines Fig S8. External validation of tumor-intrinsic TGF-β signaling across preclinical and clinical SCLC datasets Figure S9. Increased Frequency of Hyperprogressive Disease with Dual TGF-β/PD-L1 Blockade Compared With PD-1/PD-L1–based Regimens
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S9 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Figure S1. Adverse Events Following Treatment with Bintrafusp alfa Figure S2. Progression-free Survival and Overall Survival for All Arms Figure S3. Transcriptional Differences Underlying Clinical Benefit Figure S4. Comparison of HPD rates and survival between bintrafusp alfa and historical topotecan-based controls in relapsed SCLC Figure S5. Comparison of hyperprogressive disease with dual TGF-β/PD-L1 blockade (bintrafusp alfa) across tumor types. Figure S6. Distribution of SCLC Molecular Subtypes and Associated Gene Expression Differences n HPD and non-HPD Patients Figure S7. Functional Effects of TGF-β Signaling and Bintrafusp alfa in SCLC Cell Lines Fig S8. External validation of tumor-intrinsic TGF-β signaling across preclinical and clinical SCLC datasets Figure S9. Increased Frequency of Hyperprogressive Disease with Dual TGF-β/PD-L1 Blockade Compared With PD-1/PD-L1–based Regimens
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods-1 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Trial Schema; Gating strategy; KEY RESOURCES table
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods-1 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Trial Schema; Gating strategy; KEY RESOURCES table
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods-2 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Clinical Trial Protocol, IRB amendments and DSMB recommendations
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods-2 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Clinical Trial Protocol, IRB amendments and DSMB recommendations
- 17 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (8) , OF1-OF21
Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Stromal immunosuppressive pathways are key modulators of response to immune checkpoint inhibitors, but the tumor-intrinsic consequences of blocking these pathways remain incompletely defined. We conducted a clinical trial of bintrafusp alfa, a bifunctional PD-L1/TGFβ inhibitor, in small cell lung cancer (SCLC). Among 34 evaluable patients, 18% had partial responses, 20% stable disease, and 62% progressive disease; 38% of progressors met the criteria for hyperprogressive disease (HPD). HPD was also observed across other tumor types (n = 450), in higher frequencies with bintrafusp alfa than PD-(L)1 blockade alone. Blood and tumor profiling showed that HPD correlated with systemic immune suppression and elevated TGFβ signaling. Functional studies demonstrated that tumor-intrinsic TGFβ signaling restrains proliferation in a subset of SCLC; pathway blockade triggers hyperproliferation. External validation across cell lines and tumor samples confirmed a tumor-intrinsic TGFβ–high transcriptional state associated with inferior survival. These findings identify a context-dependent, growth-constraining function of TGFβ and support tumor-intrinsic biomarker guidance while targeting stromal immunosuppressive pathways. Significance: This study identifies tumor-intrinsic TGFβ signaling as a context-dependent growth restraint in SCLC and a driver of HPD following TGFβ blockade. A reproducible TGFβ–high mesenchymal state is linked to inferior survival, supporting biomarker-guided use of TGFβ–targeted immunotherapy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (8) , OF1-OF21
Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Stromal immunosuppressive pathways are key modulators of response to immune checkpoint inhibitors, but the tumor-intrinsic consequences of blocking these pathways remain incompletely defined. We conducted a clinical trial of bintrafusp alfa, a bifunctional PD-L1/TGFβ inhibitor, in small cell lung cancer (SCLC). Among 34 evaluable patients, 18% had partial responses, 20% stable disease, and 62% progressive disease; 38% of progressors met the criteria for hyperprogressive disease (HPD). HPD was also observed across other tumor types (n = 450), in higher frequencies with bintrafusp alfa than PD-(L)1 blockade alone. Blood and tumor profiling showed that HPD correlated with systemic immune suppression and elevated TGFβ signaling. Functional studies demonstrated that tumor-intrinsic TGFβ signaling restrains proliferation in a subset of SCLC; pathway blockade triggers hyperproliferation. External validation across cell lines and tumor samples confirmed a tumor-intrinsic TGFβ–high transcriptional state associated with inferior survival. These findings identify a context-dependent, growth-constraining function of TGFβ and support tumor-intrinsic biomarker guidance while targeting stromal immunosuppressive pathways. Significance: This study identifies tumor-intrinsic TGFβ signaling as a context-dependent growth restraint in SCLC and a driver of HPD following TGFβ blockade. A reproducible TGFβ–high mesenchymal state is linked to inferior survival, supporting biomarker-guided use of TGFβ–targeted immunotherapy.
- Open Access
- 4 June 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (2) , 201203
Engineering potent TILs from an immune-excluded tumor: Insights from chondrosarcoma
- 4 June 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (2) , 201203
Open AccessEngineering potent TILs from an immune-excluded tumor: Insights from chondrosarcoma
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Potent Cytotoxic Tumor-Infiltrating Lymphocytes Can Be Generated from Immune-Excluded Chondrosarcomas Using Regulatable Membrane-Bound IL15
Supplementary Table S1: IHC antibody clones and dilution factors
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Potent Cytotoxic Tumor-Infiltrating Lymphocytes Can Be Generated from Immune-Excluded Chondrosarcomas Using Regulatable Membrane-Bound IL15
Supplementary Table S1: IHC antibody clones and dilution factors
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video S2 from Potent Cytotoxic Tumor-Infiltrating Lymphocytes Can Be Generated from Immune-Excluded Chondrosarcomas Using Regulatable Membrane-Bound IL15
Video S2: Real-time tracking of TIL infiltration into tumor spheroids. Autologous tumor spheroids are labeled by Deep Red Cell Tracker dye (Red) and co-culture with TIL pre-labeled with CFSE tracker dye (Green). TIL infiltration into the autologous spheroids were imaged for 24 hrs with 1 hour time interval.
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S2 from Potent Cytotoxic Tumor-Infiltrating Lymphocytes Can Be Generated from Immune-Excluded Chondrosarcomas Using Regulatable Membrane-Bound IL15
Video S2: Real-time tracking of TIL infiltration into tumor spheroids. Autologous tumor spheroids are labeled by Deep Red Cell Tracker dye (Red) and co-culture with TIL pre-labeled with CFSE tracker dye (Green). TIL infiltration into the autologous spheroids were imaged for 24 hrs with 1 hour time interval.
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Potent Cytotoxic Tumor-Infiltrating Lymphocytes Can Be Generated from Immune-Excluded Chondrosarcomas Using Regulatable Membrane-Bound IL15
Supplementary Figure S8: Correlation of immune infiltration (IHC) and gene expression profiles
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Potent Cytotoxic Tumor-Infiltrating Lymphocytes Can Be Generated from Immune-Excluded Chondrosarcomas Using Regulatable Membrane-Bound IL15
Supplementary Figure S8: Correlation of immune infiltration (IHC) and gene expression profiles
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video S1 from Potent Cytotoxic Tumor-Infiltrating Lymphocytes Can Be Generated from Immune-Excluded Chondrosarcomas Using Regulatable Membrane-Bound IL15
Video S1: ACZ dependent killing of autologous tumor cells by TIL. Autologous tumor cells were labeled by mCherry and co-cultured with non-engineered or cytoTIL15 cells +/- 25 µM ACZ at an effector to target ratio of 20:1. Confluency of the tumor cells as readout by mCherry was analyzed.
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S1 from Potent Cytotoxic Tumor-Infiltrating Lymphocytes Can Be Generated from Immune-Excluded Chondrosarcomas Using Regulatable Membrane-Bound IL15
Video S1: ACZ dependent killing of autologous tumor cells by TIL. Autologous tumor cells were labeled by mCherry and co-cultured with non-engineered or cytoTIL15 cells +/- 25 µM ACZ at an effector to target ratio of 20:1. Confluency of the tumor cells as readout by mCherry was analyzed.